Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

The recent FDA approval of Vizz (LNZ100) by LENZ Therapeutics is generating considerable excitement in the optometric community, and for good reason. As Marc Bloomenstein, OD, FAAO, shared, this milestone offers optometrists a “formidable option” to expand how they manage presbyopia—one that’s both innovative and empowering for patients.

“This is that ‘and’ we get to offer,” Bloomenstein said. “We now have a new option that may allow patients to get out there and do the things they want to do without thinking about contacts or spectacles.”

Vizz is a once-daily, preservative-free eye drop formulated with 1.44% aceclidine, designed to temporarily improve near vision in adults with presbyopia. It works by reducing the pupil size to create a pinhole effect, increasing depth of focus. For patients who struggle with reading glasses or bifocals, Vizz represents a discreet, non-invasive alternative with minimal disruption to their daily routines.

Bloomenstein acknowledged that this solution won’t be for every patient—but emphasized the importance of expanding the therapeutic toolkit for presbyopia. “Not every patient is going to be interested in a therapeutic option like this,” he said, “but so many might be. I love walking into the exam lane and being able to say, ‘Hey, we have something new.’”

The enthusiasm for Vizz reflects a broader shift in eye care toward personalized treatment. Patients increasingly want options that align with their lifestyles, and clinicians want solutions that offer efficacy without compromise. With Vizz, optometrists now have the opportunity to engage in a more nuanced conversation about vision correction—one that goes beyond lenses and surgeries.

As Bloomenstein put it, “It’s exciting. I’m excited as a professional—we should all be excited.”

The approval of Vizz signals momentum in presbyopia innovation. With more patients seeking freedom from glasses, this drop may help redefine what's possible in non-surgical correction—and open the door for further advancements in pharmacologic eye care.